PBM-Owned vs Independent Specialty Pharmacy Competitive Analysis

Thesis

The sharper the therapy’s clinical complexity and the narrower the patient population, the stronger the case for independent or specialist SPs. The broader and more commoditized the therapy, the harder it is to avoid PBM-owned SP inclusion because payer access and volume matter more than differentiated clinical service.

Implications

For LDD network design: Manufacturers should treat limited distribution as the main point of control. Where the brand can choose one to four SPs, selection should prioritize therapeutic expertise, patient-level data, REMS or C&GT readiness, and pharmacy-hub coordination rather than defaulting to PBM scale.

For broad specialty launches: PBM-owned SPs may be necessary for volume and formulary access, but buyers should include independent or health-system partners when they need transparency, clinical differentiation, or leverage against PBM channel conflicts.

For PBM-owned SP diligence: Probe data-sharing limits, biosimilar substitution pressure, SaveOnSP or maximizer exposure, patient routing rules, affiliate reimbursement economics, and how firewall protections work when the parent PBM has competing incentives.

For reform monitoring: Arkansas-style divestiture, FTC enforcement, delinking laws, and federal PBM proposals could erode structural steerage over time. Network contracts should preserve optionality to rebalance toward independents or health-system SPs if PBM ownership restrictions spread.

Market Overview

The U.S. specialty pharmacy market generates approximately $265 billion in gross dispensing revenue (2025 estimate), with total specialty drug spend exceeding $340 billion when including physician-administered drugs and non-pharmacy channels. Three PBM-owned specialty pharmacies dominate:

SP	Parent PBM	Est. SP Revenue (2023-2024)	Captive Lives
CVS Specialty	CVS Caremark	~$73-80B	~110M Caremark lives
Accredo	Express Scripts/Evernorth	~$59-70B	~120M Express Scripts lives
OptumRx Specialty	OptumRx/UnitedHealth	~$46-55B	~80M+ UHC lives
Combined	—	~$178-205B	~310M managed lives

The Big Three command 50-60% of total specialty dispensing volume and 66-68% of specialty dispensing revenue. This share grew from 54% in 2016 — concentration has increased, not decreased, over the past decade.

Independent specialty pharmacies — PANTHERx Rare, Orsini, BrightSpring/Onco360, Amber Specialty, Option Care Health, Walgreens Specialty, and dozens of regional players — contest the remaining 32-40% of the market. Health system SPs, enabled primarily by Shields Health Solutions (Sycamore Partners-majority since August 2025, with a $3.5B Evernorth/Cigna preferred equity stake added September 2025 — structurally distinct from both the Big-3 PBM-owned tier and the unaffiliated independents), are the fastest-growing segment, growing from 15% to 27% of URAC-accredited SP locations between 2017-2024.

Competitive Framework: 8-Dimension Comparison

Dimension	PBM-Owned SP	Independent SP	Advantage
Formulary Access	Structural advantage: PBM controls formulary design, can mandate or preference its own SP	Must negotiate network inclusion; may be excluded from narrow networks	PBM-Owned
Data Transparency	Limited: manufacturers report restricted data sharing, opaque outcomes reporting, minimal patient-level visibility	Strong: independents typically provide granular patient-level data, transparent outcomes, and manufacturer-accessible dashboards	Independent
Clinical Specialization	Broad but shallow: high volume across many TAs; CVS has 23 walk-in locations; Accredo has 15 TRCs	Deep and narrow: PANTHERx (65+ rare diseases), Orsini (12 C&GT therapies), Onco360 (#1 independent oncology)	Independent
Manufacturer Relationship	Transactional: PBM commercial interests may conflict with manufacturer goals; biosimilar mandates (Cordavis, Quallent, Nuvaila) can displace brand products	Aligned: no formulary conflicts; manufacturer retains control over brand positioning and patient experience	Independent
Patient Experience	Mixed: scale enables convenience (CVS Specialty Connect retail pickup) but call center models can feel impersonal; SaveOnSP maximizer creates patient friction	Generally strong: smaller caseloads per pharmacist; PANTHERx and Orsini report higher patient satisfaction in rare/CGT	Independent
Cost Structure	Lower per-unit cost at scale; FTC documented higher reimbursement rates at affiliated vs independent pharmacies	Higher per-unit cost; offset by lower waste, better adherence, and manufacturer willingness to pay premium for data/control	PBM-Owned
Regulatory Risk	High: FTC investigation, CAA 2026, Arkansas divestiture law, 15+ state bills pending — all target PBM-SP integration	Low: benefit from every reform that restricts PBM self-preferencing	Independent
LDD Network Position	Included in most LDD networks by default (PBM leverage)	Must earn inclusion; 68% of LDD drugs limited to 1-4 SPs — manufacturers choose quality over scale	Depends on product

Arkansas Divestiture and the State Legislative Wave

Arkansas Act 624 (HB 1150), signed April 2025, is the first state law requiring PBMs to divest ownership of pharmacies. Key details:

Effective: January 2026 (preliminary injunction issued July 2025 on Commerce Clause grounds)
Mechanism: Prohibits PBMs from owning, operating, or having financial interest in pharmacies
Transition: Permits through September 2027 for rare/orphan drug dispensing
Legal question: ERISA preemption is the central issue — self-funded employer plans governed by ERISA may argue state PBM laws are preempted by federal statute

Replication risk for PBMs is real. As of early 2026, 15+ states have introduced similar divestiture or “delinking” bills. Colorado and California have enacted PBM delinking laws (prohibiting PBM compensation tied to drug prices). 270+ utilization management reform bills and 85+ pharmacy network protection bills were active in 2025 state sessions alone.

If divestiture spreads:

PBM-owned SPs must create structurally separated subsidiaries in affected states
Operational complexity and cost increase; structural steerage advantage erodes
Independent SPs gain immediate market share in affected states
Manufacturer LDD network decisions shift toward clinical quality rather than PBM leverage

Federal action compounds the threat: the FTC-Express Scripts settlement (February 2026) requires net-cost-based member cost-sharing and direct rebate pass-through by 2028. The Break Up Big Medicine Act (Warren-Hawley, February 2026) would ban common ownership of insurer/PBM with provider/MSO entities outright.

Competitive Dynamics

PBM Biosimilar Mandates Create Manufacturer Tension

PBM-owned SPs are increasingly used as channels for PBM-affiliated biosimilars:

CVS/Cordavis mandates Hyrimoz (biosimilar adalimumab), excluding brand Humira from Caremark formularies
Express Scripts/Quallent and OptumRx/Nuvaila follow similar private-label biosimilar strategies
Impact on manufacturers: Brand manufacturer hub programs become irrelevant for patients steered to PBM-mandated biosimilars. Independents maintaining brand access preserve the manufacturer relationship.

Health System SPs as Third Force

Hospital-owned SPs, enabled by Shields Health Solutions (80+ health systems, $700M+ revenue), are emerging as a third competitive tier distinct from both PBM-owned and traditional independents:

Clinically embedded (pharmacists alongside treating physicians)
340B pricing provides structural margin advantage
Hospitals increasingly demand hub programs route to their own SP
Growing from 15% to 27% of URAC-accredited SP locations (2017-2024)

Cell & Gene Therapy Readiness Favors Specialists

Ultra-cold storage, chain-of-identity tracking, REMS coordination, and 15-year outcome registry capabilities are concentrated among a handful of SPs. Orsini (12 C&GT therapies), Accredo (GeneAXS platform), CVS (most LDD launches), and PANTHERx lead this capability set. Most PBM-owned SPs lack depth in C&GT beyond their flagship centers.

LDD Network Design Favors Manufacturer Control

For 68% of limited distribution drugs, the manufacturer controls pharmacy selection among 1-4 pharmacies. This is the decision space where PBM-owned vs independent matters most:

LDD Network Size	% of LDD Drugs	Manufacturer Control	SP Selection Dynamic
Exclusive (1 SP)	34%	Total	Manufacturer selects on clinical quality; PBM leverage irrelevant
2-4 SPs	34%	High	Manufacturer can include or exclude PBM-owned; clinical and data criteria dominant
5-10 SPs	20%	Moderate	Mix of PBM-owned for volume + independents for quality
Open network	12%	Low	PBM formulary design controls patient routing

Implication: For nearly 70% of specialty drugs on LDD networks, manufacturers have the power to choose independent SPs over PBM-owned without commercial penalty. The remaining 30% on open networks are where PBM structural advantage is most concentrated.

IRA Part D Redesign Reshapes SP Economics

The $2,000 OOP cap (effective 2025) and Manufacturer Discount Program (MDP) alter the economic relationship between manufacturers and SPs. Higher patient volumes (more patients starting/staying on therapy as financial barriers drop) flow through SP dispensing channels, but MDP obligations compress the economics. See Part D Redesign Impact on Copay Assistance Economics for the detailed financial model.

Manufacturer Decision Matrix

Product Profile	Recommended SP Strategy	Rationale
Commodity specialty (autoimmune, diabetes, established MOAs)	PBM-owned primary + 1-2 independents	Volume-driven; formulary access is paramount; independence provides competitive leverage and data
Rare disease (<10K patients)	Independent-led: PANTHERx, Orsini	Clinical depth, patient-level data, manufacturer control; PBM scale irrelevant for small populations
Cell & gene therapy	Specialist-only: Orsini, Accredo/GeneAXS, CVS	Ultra-cold, chain-of-identity, registry capabilities required; very few SPs qualify
Oncology (oral)	BrightSpring/Onco360 + PBM-owned for formulary	Onco360 is #1 independent oncology SP; PBM inclusion needed for broad formulary access
Infusion therapy	Option Care Health (home) + health system SPs	Site-of-care steering favors home/alternate-site; Option Care is largest independent home infusion
Biosimilar	PBM-owned (if aligned with PBM biosimilar strategy) or independent (if brand manufacturer)	PBM mandates favor affiliated SPs; brand manufacturers should hedge with independents
Health system-dispensed	Shields-enabled health system SP	340B advantage; clinical embedding; growing hospital demand for in-network inclusion

General principle: The narrower the patient population and the more clinically complex the therapy, the stronger the case for independent SPs. The broader the population and the more commoditized the drug class, the harder it is to avoid PBM-owned channels.

Scenario Analysis: What Happens If PBM Divestiture Spreads Nationally?

Scenario 1: Arkansas stays isolated (40% probability)

PBMs adjust operations in one state; national dynamics unchanged
Independent SP share remains at ~32-34%
Status quo with incremental FTC enforcement pressure

Scenario 2: 5-10 states adopt divestiture by 2028 (35% probability)

PBMs create structurally separated SP subsidiaries in affected states
Independent SPs gain 5-8 percentage points of share in affected states
National independent SP share rises to ~36-40%
Operating complexity drives PBM SP costs higher, eroding their scale advantage

Scenario 3: Federal divestiture or FTC-enforced separation (15-20% probability)

PBM-owned SP share drops from 66-68% toward 45-55% over 3-5 years
Independent SPs and health system SPs rapidly absorb freed volume
LDD network design shifts entirely to clinical quality and data transparency criteria
Hub vendor selection becomes fully merit-based rather than structurally constrained
Specialty pharmacy becomes a higher-margin, more clinically differentiated market

Scenario 4: ERISA preemption kills state reform (10% probability)

Federal courts rule state PBM laws preempted for self-funded plans (~60% of commercial market)
PBM structural advantage preserved for the majority of commercially insured lives
Reform limited to fully insured market and Medicare; independent SPs gain less than expected

Key Takeaways

PBM-owned SPs hold 66-68% share built on structural advantage, not clinical superiority. FTC documentation of self-preferencing and higher affiliated reimbursement rates confirms this.
Regulatory momentum favors independents. Arkansas divestiture, FTC settlements, CAA 2026, and 15+ pending state bills all target the structural integration that sustains PBM-owned SP dominance.
Data transparency is the clearest independent SP advantage. Manufacturers consistently report better patient-level data, outcomes visibility, and program control from independent SPs.
ERISA preemption is the key legal wildcard. If state divestiture laws are struck down on ERISA grounds for self-funded plans (~60% of commercially insured), the structural reform impact is dramatically reduced.
Health system SPs are the fastest-growing segment and represent a third competitive force. Shields Health Solutions is the primary enablement platform.
Biosimilar mandates are the near-term manufacturer pain point. PBM private-label biosimilar programs can render brand hub programs irrelevant overnight.
Cell & gene therapy readiness is the capability frontier. Very few SPs — PBM-owned or independent — have validated ultra-cold, chain-of-identity, and long-term registry infrastructure.
Manufacturer SP strategy should be product-profile-driven, not one-size-fits-all. Rare disease and C&GT demand independents; commodity specialty requires PBM-owned inclusion.

Specialty Pharmacy Competitive Landscape
Big Three PBM Specialty Pharmacy Operations
PBM Reform Implications for Pharma Services Vendors
PBM Ecosystem & Reform
SP Accreditation & Network Design
PANTHERx Rare
Shields Health Solutions
BrightSpring Health Services